Candriam S.C.A. Aerie Pharmaceuticals Inc Transaction History

Candriam S.C.A.

$17.1 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	BUY	$6.37 - $15.23 $909,285 - $2.17 Million	142,745 New	142,745 $2.16 Million
Q1 2022 May 13, 2022	SELL	$5.64 - $9.8 $851,640 - $1.48 Million	-151,000 Closed	0 $0
Q4 2021 Feb 10, 2022	BUY	$7.02 - $13.33 $1.06 Million - $2.01 Million	151,000 New	151,000 $1.06 Million
Q2 2021 Jul 20, 2021	SELL	$15.16 - $18.97 $8.74 Million - $10.9 Million	-576,495 Closed	0 $0
Q4 2020 Jan 22, 2021	SELL	$9.12 - $14.49 $139,581 - $221,769	-15,305 Reduced 2.59%	576,495 $7.79 Million
Q2 2020 Jul 23, 2020	SELL	$12.0 - $16.13 $936,000 - $1.26 Million	-78,000 Reduced 11.65%	591,800 $8.74 Million
Q4 2019 Jan 21, 2020	SELL	$17.72 - $25.1 $531,600 - $753,000	-30,000 Reduced 4.29%	669,800 $16,000
Q3 2019 Oct 21, 2019	BUY	$18.41 - $28.0 $1.75 Million - $2.66 Million	95,000 Added 15.71%	699,800 $13,000
Q1 2019 May 02, 2019	BUY	$36.32 - $49.25 $4.58 Million - $6.21 Million	126,000 Added 26.32%	604,800 $28.7 Million
Q4 2018 Feb 14, 2019	BUY	$33.0 - $60.04 $5.02 Million - $9.13 Million	152,000 Added 46.51%	478,800 $17.3 Million
Q3 2018 Nov 07, 2018	BUY	$56.15 - $73.9 $11.5 Million - $15.2 Million	205,100 Added 168.53%	326,800 $20.1 Million
Q2 2018 Aug 14, 2018	BUY	$47.85 - $70.45 $2.04 Million - $3.01 Million	42,700 Added 54.05%	121,700 $8.22 Million
Q1 2018 May 09, 2018	BUY	$51.15 - $61.0 $358,050 - $427,000	7,000 Added 9.72%	79,000 $4.29 Million
Q4 2017 Feb 07, 2018	BUY	$50.85 - $65.1 $661,050 - $846,299	13,000 Added 22.03%	72,000 $4.3 Million
Q3 2017 Nov 03, 2017	BUY	$48.6 - $60.1 $2.87 Million - $3.55 Million	59,000	59,000 $2.87 Million

Others Institutions Holding AERI

# of Institutions

Shares Held

2.4M

Call Options Held

Put Options Held

View Full List

About AERIE PHARMACEUTICALS INC

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

More about AERI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

News

Stay updated on Candriam S.C.A. with notifications on news.

Account